Advertisement

Molecular Medicine

, Volume 18, Issue 3, pp 379–388 | Cite as

Expression of Interleukin-8 Receptor CXCR2 and Suppressor of Cytokine Signaling-3 in Astrocytic Tumors

  • Penelope Korkolopoulou
  • Georgia Levidou
  • Elias A. El-Habr
  • Christos Adamopoulos
  • Vassilis Samaras
  • Athanasios Zisakis
  • Nikolaos Kavantzas
  • Efstathios Boviatsis
  • Paraskevi Fragkou
  • Athanasios G. Papavassiliou
  • Efstratios Patsouris
  • Christina Piperi
Research Article

Abstract

The aim was to expand recently published information regarding the significance of the interleukin (IL)-8/p-STAT-3 (signal transducer and activator of transcription) pathway in astrocytomas, focusing on the IL-8 receptor, chemokine (C-X-C motif) receptor 2 (CXCR2), and the STAT-3 inhibitor SOCS-3 (suppressors of cytokine signaling). A total of 91 paraffin-embedded human astrocytoma tissues (grades II-IV) were investigated for the association of SOCS-3 and CXCR2 expression with clinicopathologic and morpho-metric microvascular characteristics, vascular endothelial growth factor (VEGF), IL-8 and p-STAT-3 expression and patient survival. Peripheral IL-8 secretion levels were assessed by enzyme-linked immunosorbent spot (ELISPOT). SOCS-3, p-STAT-3 and CXCR2 protein levels were also quantified by Western immunoblotting in six cases, and the protein levels of SOCS-3 and CXCR2 were correlated with the immunohistochemical expression of the respective proteins. All CXCR2-positive cases by Western immunoblotting displayed increased peripheral IL-8 secretion levels. Treatment of primary glioblastoma cell cultures with exogenous IL-8 enhanced proliferation, and this effect was inhibited by treatment with a neutralizing anti-CXCR2 antibody. SOCS-3 and CXCR2 were expressed by neoplastic astrocytes in 92.4% and 48.78% of cases, respectively, with their levels increasing with histological grade and extent of necrosis. VEGF expression and microvessel density, CXCR2 and IL-8 levels were interrelated. SOCS-3 and p-STAT-3 were co-expressed in 85.7% of cases, although they were not interrelated. In univariate survival analysis, increased SOCS-3 expression and the presence of CXCR2 adversely affected survival, whereas in multivariate analysis, only CXCR2 remained significant. The prognostic significance of CXCR2 was validated in an independent set of 63 patients. Our data implicate IL-8/CXCR2 signaling pathway in the progression and regulation of angiogenesis in astrocytomas and provide a rationale for CXCR2 therapeutic exploitation in these tumors.

References

  1. 1.
    Maher EA, et al. (2001) Malignant glioma: genetics and biology of a grave matter. Genes Dev. 15:1311–33.CrossRefGoogle Scholar
  2. 2.
    Brat DJ, Bellail AC, Van Meir EG. (2005) The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro. Oncol. 7:122–33.CrossRefGoogle Scholar
  3. 3.
    Murphy PM, Tiffany HL. (1991) Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science. 253:1280–3.CrossRefGoogle Scholar
  4. 4.
    Raychaudhuri B, Vogelbaum MA. (2011) IL-8 is a mediator of NFkB induced invasion by gliomas. J. Neurooncol. 101:227–35.CrossRefGoogle Scholar
  5. 5.
    Richardson RM, Marjoram RJ, Barak LS, Snyderman R. (2003) Role of the cytoplasmic tails of CXCR1 and CXCR2 in mediating leukocyte migration, activation, and regulation. J. Immunol. 170:2904–11.CrossRefGoogle Scholar
  6. 6.
    Brantley EC, et al. (2008) Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin. Cancer Res. 14:4694–704.CrossRefGoogle Scholar
  7. 7.
    Piperi C, et al. (2011) Prognostic significance of IL-8-STAT-3 pathway in astrocytomas: correlation with IL-6, VEGF and microvessel morphometry. Cytokine. 55:387–95.CrossRefGoogle Scholar
  8. 8.
    de la Iglesia N, et al. (2008) Deregulation of a STAT3-interleukin 8 signaling pathway promotes human glioblastoma cell proliferation and invasiveness. J. Neurosci. 28:5870–8.CrossRefGoogle Scholar
  9. 9.
    Wormald S, Hilton DJ. (2004) Inhibitors of cytokine signal transduction. J. Biol. Chem. 279:821–4.CrossRefGoogle Scholar
  10. 10.
    Baker BJ, Akhtar LN, Benveniste EN. (2009) SOCS1 and SOCS3 in the control of CNS immunity. Trends Immunol. 30:392–100.CrossRefGoogle Scholar
  11. 11.
    Zhou H, et al. (2007) Reciprocal regulation of SOCS 1 and SOCS3 enhances resistance to ionizing radiation in glioblastoma multiforme. Clin. Cancer Res. 13:2344–53.CrossRefGoogle Scholar
  12. 12.
    Matsuo Y, et al. (2009) CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int. J. Cancer. 125:1027–37.CrossRefGoogle Scholar
  13. 13.
    Li A, et al. (2005) Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis. 8:63–71.CrossRefGoogle Scholar
  14. 14.
    Louis DN, et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97–109.CrossRefGoogle Scholar
  15. 15.
    Samaras V, et al. (2007) Application of the ELISPOT method for comparative analysis of interleukin (IL)-6 and IL-10 secretion in peripheral blood of patients with astroglial tumours. Mol. Cell. Biochem. 304:343–51.CrossRefGoogle Scholar
  16. 16.
    Zisakis A, et al. (2007) Comparative analysis of peripheral and localised cytokine secretion in glioblastoma patients. Cytokine. 39:99–105.CrossRefGoogle Scholar
  17. 17.
    Korkolopoulou P, et al. (2002) Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms. Neuropathol. Appl. Neurobiol. 28:57–66.CrossRefGoogle Scholar
  18. 18.
    Korkolopoulou P, et al. (2007) Expression of hypoxia-related tissue factors in astrocytic gliomas: a multivariate survival study with emphasis upon carbonic anhydrase IX. Hum. Pathol. 38:629–38.CrossRefGoogle Scholar
  19. 19.
    Hsieh FY, Lavori PW. (2000) Sample-size calculations for the Cox proportional hazards regression model with nonbinary covariates. Control Clin. Trials. 21:552–60.CrossRefGoogle Scholar
  20. 20.
    Lachin JM, Foulkes MA. (1986) Evaluation of sample size and power analysis of survival with allowance for nonuniform patient entry, losses to follow-up noncompliance and stratification. Biometrics. 42:507–19.CrossRefGoogle Scholar
  21. 21.
    Desbaillets I, Diserens AC, Tribolet N, Hamou MF, Van Meir EG. (1997) Upregulation of interleukin 8 by oxygen-deprived cells in glioblastoma suggests a role in leukocyte activation, chemotaxis, and angiogenesis. J. Exp. Med. 186:1201–12.CrossRefGoogle Scholar
  22. 22.
    Zhou Y, Larsen PH, Hao C, Yong VW. (2002) CXCR4 is a major chemokine receptor on glioma cells and mediates their survival. J. Biol. Chem. 277:49481–7.CrossRefGoogle Scholar
  23. 23.
    Van Meir E, et al. (1992) Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer Res. 52:4297–305.PubMedGoogle Scholar
  24. 24.
    Gabellini C, et al. (2009) Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur. J. Cancer. 45:2618–27.CrossRefGoogle Scholar
  25. 25.
    Samaras V, et al. (2009) Analysis of interleukin (IL)-8 expression in human astrocytomas: associations with IL-6, cyclooxygenase-2, vascular endothelial growth factor, and microvessel morphometry. Human Immunol. 70:391–7.CrossRefGoogle Scholar
  26. 26.
    Oladipo O, et al. (2011) The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br. J. Cancer. 104:480–7.CrossRefGoogle Scholar
  27. 27.
    Liu Z, Yang L, Xu J, Zhang X, Wang B. (2011) Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J. Surg. Res. 166:241–6.CrossRefGoogle Scholar
  28. 28.
    Cheng WL, et al. (2011) Overexpression of CXCL1 and its receptor CXCR2 promote tumor invasion in gastric cancer. Ann. Oncol. 22:2267–76.CrossRefGoogle Scholar
  29. 29.
    Yamamoto M, et al. (2008) TSU68 prevents liver metastasis of colon cancer xenografts by modulating the premetastatic niche. Cancer Res. 68:9754–62.CrossRefGoogle Scholar
  30. 30.
    Yang G, et al. (2010) CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin. Cancer Res. 16:3875–86.CrossRefGoogle Scholar
  31. 31.
    Wang D, et al. (2000) MGSA/GRO-mediated melanocyte transformation involves induction of Ras expression. Oncogene. 19:4647–59.CrossRefGoogle Scholar
  32. 32.
    Burger M, Hartmann T, Burger JA, Schraufstatter I. (2005) KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway. Oncogene. 24:2067–75.CrossRefGoogle Scholar
  33. 33.
    Waugh DJ, Wilson C. (2008) The interleukin-8 pathway in cancer. Clin. Cancer Res. 14:6735–41.CrossRefGoogle Scholar
  34. 34.
    Singh S, Varney M, Singh RK. (2009) Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69:411–5.CrossRefGoogle Scholar
  35. 35.
    Li A, et al. (2011) Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am. J. Pathol. 178:1340–9.CrossRefGoogle Scholar
  36. 36.
    Martini M, et al. (2008) Prognostic relevance of SOCS3 hypermethylation in patients with glioblastoma multiforme. Int. J. Cancer. 123:2955–60.CrossRefGoogle Scholar
  37. 37.
    Puhr M, et al. (2009) Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways. Cancer Res. 69:7375–84.CrossRefGoogle Scholar
  38. 38.
    Sasi W, Jiang WG, Sharma A, Mokbel K. (2010) Higher expression levels of SOCS 1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. BMC Cancer. 10:178.CrossRefGoogle Scholar
  39. 39.
    Brender C, et al. (2001) STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood. 97:1056.CrossRefGoogle Scholar
  40. 40.
    Huang WT, et al. (2009) Expression of signal transducer and activator of transcription 3 and suppressor of cytokine signaling 3 in urothelial carcinoma. Kaohsiung J. Med. Sci. 25:640–6.CrossRefGoogle Scholar
  41. 41.
    Lu Y, et al. (2006) Loss of SOCS3 gene expression converts STAT3 function from anti-apoptotic to pro-apoptotic. J. Biol. Chem. 281:36683–90.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2012

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Penelope Korkolopoulou
    • 1
  • Georgia Levidou
    • 1
  • Elias A. El-Habr
    • 1
  • Christos Adamopoulos
    • 2
  • Vassilis Samaras
    • 3
  • Athanasios Zisakis
    • 2
  • Nikolaos Kavantzas
    • 1
  • Efstathios Boviatsis
    • 4
  • Paraskevi Fragkou
    • 1
  • Athanasios G. Papavassiliou
    • 2
  • Efstratios Patsouris
    • 1
  • Christina Piperi
    • 2
  1. 1.First Department of Pathology, “Laiko” HospitalUniversity of Athens Medical SchoolAthensGreece
  2. 2.Department of Biological ChemistryUniversity of Athens Medical SchoolAthensGreece
  3. 3.Department of Pathology“Red Cross” HospitalAthensGreece
  4. 4.Department of NeurosurgeryUniversity of Athens Medical School, “Evangelismos” HospitalAthensGreece

Personalised recommendations